Targeting MMP-2 to treat ischemic heart injury

Basic Research in Cardiology

Volumn 109, Issue 4, 2014, Pages

  Hughes, Bryan G ^a   Schulz, Richard ^a  

^a UNIVERSITY OF ALBERTA   (Canada)

Author keywords

Doxycycline; Ischemic heart disease; Matrix metalloproteinase; MMP inhibitors; MMP 2; Myocardial infarction

Indexed keywords

1,10 PHENANTHROLINE; 5 ETHOXYMETHOXY N HYDROXY 2 METHYL 4 (4 PHENOXYBENZAMIDO)PENTANAMIDE; ALPHA ACTININ; BIOLOGICAL MARKER; CONNECTIN; CP 471474; DOXYCYCLINE; GELATINASE A; GELATINASE B; ILOMASTAT; INTERSTITIAL COLLAGENASE; MARIMASTAT; MATRIX METALLOPROTEINASE INHIBITOR; MYOSIN LIGHT CHAIN; MYOSIN LIGHT CHAIN 1; NEUTROPHIL COLLAGENASE; PG 116800; PGE 530742; TISAM; TISSUE INHIBITOR OF METALLOPROTEINASE 3; TISSUE INHIBITOR OF METALLOPROTEINASE 4; TROPONIN I; UNCLASSIFIED DRUG; CARDIOVASCULAR AGENT;

ACUTE CORONARY SYNDROME; CLINICAL TRIAL (TOPIC); DISEASE ASSOCIATION; DRUG EFFICACY; ENZYME ACTIVITY; ENZYME BLOOD LEVEL; ENZYME INHIBITION; ENZYME LOCALIZATION; ENZYME REGULATION; EX VIVO STUDY; HEART FUNCTION; HEART INFARCTION; HEART INFARCTION PREVENTION; HEART LEFT VENTRICLE FAILURE; HEART PROTECTION; HEART RIGHT VENTRICLE VOLUME; HEART SURGERY; HEART VENTRICLE REMODELING; HUMAN; IN VIVO STUDY; ISCHEMIC HEART DISEASE; KNOCKOUT MOUSE; MULTICENTER STUDY (TOPIC); NEWBORN HYPOXIA; NONHUMAN; PHASE 2 CLINICAL TRIAL (TOPIC); PROTEIN DEGRADATION; PROTEIN TARGETING; REPERFUSION INJURY; REVIEW; ST SEGMENT ELEVATION MYOCARDIAL INFARCTION; ANIMAL; DISEASE MODEL; DRUG EFFECTS; ENZYMOLOGY; HEART MUSCLE; METABOLISM; MOLECULARLY TARGETED THERAPY; MYOCARDIAL INFARCTION; MYOCARDIAL REPERFUSION INJURY; PATHOLOGY; PATHOPHYSIOLOGY; SIGNAL TRANSDUCTION;

ANIMALS; CARDIOVASCULAR AGENTS; DISEASE MODELS, ANIMAL; HUMANS; MATRIX METALLOPROTEINASE 2; MATRIX METALLOPROTEINASE INHIBITORS; MOLECULAR TARGETED THERAPY; MYOCARDIAL INFARCTION; MYOCARDIAL REPERFUSION INJURY; MYOCARDIUM; SIGNAL TRANSDUCTION; VENTRICULAR REMODELING;

EID: 84903400123     PISSN: 03008428     EISSN: 14351803     Source Type: Journal    
DOI: 10.1007/s00395-014-0424-y     Document Type: Review

References (128)

1. Agrawal A, Romero-Perez D, Jacobsen JA, Villarreal FJ, Cohen SM (2008) Zinc-binding groups modulate selective inhibition of MMPs. ChemMedChem 3:812-820. doi:10.1002/cmdc.200700290
2. Alfonso-Jaume MA, Bergman MR, Mahimkar R, Cheng S, Jin ZQ, Karliner JS, Lovett DH (2006) Cardiac ischemia-reperfusion injury induces matrix metalloproteinase-2 expression through the AP-1 components FosB and JunB. Am J Physiol Heart Circ Physiol 291:H1838-H1846. doi:10.1152/ajpheart.00026.2006 (Pubitemid 44497691)
3. Ali MA, Cho WJ, Hudson B, Kassiri Z, Granzier H, Schulz R (2010) Titin is a target of matrix metalloproteinase-2: implications in myocardial ischemia/reperfusion injury. Circulation 122:2039-2047. doi:10.1161/ circulationaha.109.930222
4. Ali MAM, Fan X, Schulz R (2011) Cardiac sarcomeric proteins: novel intracellular targets of matrix metalloproteinase-2 in heart disease. Trends Cardiovasc Med 21:112-118. doi:10.1016/j.tcm.2012.03.008
5. Ali MAM, Cho WJ, Hudson B, Kassiri Z, Granzier H, Schulz R (2010) Titin is a target of matrix metalloproteinase-2. Circulation 122:2039-2047. doi:10.1161/circulationaha.109.930222
6. Ali MAM, Chow AK, Kandasamy AD, Fan X, West LJ, Crawford BD, Simmen T, Schulz R (2012) Mechanisms of cytosolic targeting of matrix metalloproteinase-2. J Cell Physiol 227:3397-3404. doi:10.1002/jcp.24040
7. Apple KA, Yarbrough WM, Mukherjee R, Deschamps AM, Escobar PG, Mingoia JT, Sample JA, Hendrick JW, Dowdy KB, McLean JE, Stroud RE, O'Neill TP, Spinale FG (2006) Selective targeting of matrix metalloproteinase inhibition in post-infarction myocardial remodeling. J Cardiovasc Pharmacol 47:228-235. doi:10.1097/01.fjc.0000200989.23987.b8 (Pubitemid 44384061)
8. Beery AK, Zucker I (2011) Sex bias in neuroscience and biomedical research. Neurosci Biobehav Rev 35:565-572. doi:10.1016/j.neubiorev.2010.07.002
9. Bell R, Kunuthur S, Hendry C, Bruce-Hickman D, Davidson S, Yellon D (2013) Matrix metalloproteinase inhibition protects CyPD knockout mice independently of RISK/mPTP signalling: a parallel pathway to protection. Basic Res Cardiol 108:331. doi:10.1007/s00395-013-0331-7
10. Bencsik P, Kupai K, Giricz Z, Görbe A, Pipis J, Murlasits Z, Kocsis GF, Varga-Orvos Z, Puskás LG, Csonka C, Csont T, Ferdinandy P (2010) Role of iNOS and peroxynitrite-matrix metalloproteinase-2 signaling in myocardial late preconditioning in rats. Am J Physiol Heart Circ Physiol 299:H512-H518. doi:10.1152/ajpheart.00052.2010
11. Bencsik P, Paloczi J, Kocsis GF, Pipis J, Belecz I, Varga ZV, Csonka C, Gorbe A, Csont T, Ferdinandy P (2014) Moderate inhibition of myocardial matrix metalloproteinase-2 by ilomastat is cardioprotective. Pharmacol Res 80:36-42. doi:10.1016/j.phrs.2013.12.007
12. Bergman MR, Teerlink JR, Mahimkar R, Li L, Zhu B-Q, Nguyen A, Dahi S, Karliner JS, Lovett DH (2007) Cardiac matrix metalloproteinase-2 expression independently induces marked ventricular remodeling and systolic dysfunction. Am J Physiol Heart Circ Physiol 292:H1847-H1860. doi:10.1152/ajpheart.00434.2006 (Pubitemid 46572408)
13. Bergman MR, Cheng S, Honbo N, Piacentini L, Karliner JS, Lovett DH (2003) A functional activating protein 1 (AP-1) site regulates matrix metalloproteinase 2 (MMP-2) transcription by cardiac cells through interactions with JunB-Fra1 and JunB-FosB heterodimers. Biochem J 369:485-496. doi:10.1042/bj20020707 (Pubitemid 36246232)
14. Berman B, Perez OA, Zell D (2007) Update on rosacea and anti-inflammatory-dose doxycycline. Drugs Today (Barc) 43:27-34. doi:10.1358/dot.2007.43.1.1025697 (Pubitemid 46448835)
15. Billinghurst RC, Dahlberg L, Ionescu M, Reiner A, Bourne R, Rorabeck C, Mitchell P, Hambor J, Diekmann O, Tschesche H, Chen J, VanWart H, Poole AR (1997) Enhanced cleavage of type II collagen by collagenases in osteoarthritic articular cartilage. J Clin Invest 99:1534-1545. doi:10.1172/jci119316 (Pubitemid 27163804)
16. Brooks PC, Stromblad S, Sanders LC, von Schalscha TL, Aimes RT, Stetler-Stevenson WG, Quigley JP, Cheresh DA (1996) Localization of matrix metalloproteinase MMP-2 to the surface of invasive cells by interaction with integrin alpha v beta 3. Cell 85:683-693. doi:10.1016/s0092-8674(00)81235-0 (Pubitemid 26181048)
17. Brown DL, Desai KK, Vakili BA, Nouneh C, Lee H-M, Golub LM (2004) Clinical and biochemical results of the metalloproteinase inhibition with subantimicrobial doses of doxycycline to prevent acute coronary syndromes (MIDAS) pilot trial. Arterioscler Thromb Vasc Biol 24:733-738. doi:10.1161/01.ATV.0000121571.78696.dc (Pubitemid 38451612)
18. Bulteau A-L, Lundberg KC, Ikeda-Saito M, Isaya G, Szweda LI (2005) Reversible redox-dependent modulation of mitochondrial aconitase and proteolytic activity during in vivo cardiac ischemia/reperfusion. Proc Natl Acad Sci USA 102:5987-5991. doi:10.1073/pnas.0501519102 (Pubitemid 40594242)
19. Cadete VJJ, Sawicka J, Jaswal JS, Lopaschuk GD, Schulz R, Szczesna-Cordary D, Sawicki G (2012) Ischemia/reperfusion-induced myosin light chain 1 phosphorylation increases its degradation by matrix metalloproteinase 2. FEBS J 279:2444-2454. doi:10.1111/j.1742-4658.2012.08622.x
20. Cadete VJJ, Sawicka J, Bekar LK, Sawicki G (2013) Combined subthreshold dose inhibition of myosin light chain phosphorylation and MMP-2 activity provides cardioprotection from ischaemic/reperfusion injury in isolated rat heart. Br J Pharmacol 170:380-390. doi:10.1111/bph.12289
21. Camp TM, Tyagi SC, Aru GM, Hayden MR, Mehta JL (2004) Doxycycline ameliorates ischemic and border-zone remodeling and endothelial dysfunction after myocardial infarction in rats. J Heart Lung Transplant 23:729-736. doi:10.1016/j.healun.2003.06.005 (Pubitemid 38721443)
22. Caton J, Ryan ME (2011) Clinical studies on the management of periodontal diseases utilizing subantimicrobial dose doxycycline (SDD). Pharmacol Res 63:114-120. doi:10.1016/j.phrs.2010.12.003
23. Cauwe B, Opdenakker G (2010) Intracellular substrate cleavage: a novel dimension in the biochemistry, biology and pathology of matrix metalloproteinases. Crit Rev Biochem Mol Biol 45:351-423. doi:10.3109/10409238. 2010.501783
24. Cerisano G, Buonamici P, Valenti R, Moschi G, Taddeucci E, Giurlani L, Migliorini A, Vergara R, Parodi G, Sciagrà R, Romito R, Colonna P, Antoniucci D (2014) Effects of a timely therapy with doxycycline on the left ventricular remodeling according to the pre-procedural TIMI flow grade in patients with ST-elevation acute myocardial infarction. Basic Res Cardiol 109:412. doi:10.1007/s00395-014-0412-2
25. Cerisano G, Buonamici P, Valenti R, Sciagrà R, Raspanti S, Santini A, Carrabba N, Dovellini EV, Romito R, Pupi A, Colonna P, Antoniucci D (2014) Early short-term doxycycline therapy in patients with acute myocardial infarction and left ventricular dysfunction to prevent the ominous progression to adverse remodelling: the TIPTOP trial. Eur Heart J 35:184-191. doi:10.1093/eurheartj/eht420
26. Chakraborti S, Mandal M, Das S, Mandal A, Chakraborti T (2003) Regulation of matrix metalloproteinases: an overview. Mol Cell Biochem 253:269-285. doi:10.1023/a:1026028303196
27. Cheung P-Y, Sawicki G, Wozniak M, Wang W, Radomski MW, Schulz R (2000) Matrix metalloproteinase-2 contributes to ischemia-reperfusion injury in the heart. Circulation 101:1833-1839. doi:10.1161/01.CIR.101.15.1833 (Pubitemid 30213106)
28. Chow AK, Cena J, El-Yazbi AF, Crawford BD, Holt A, Cho WJ, Daniel EE, Schulz R (2007) Caveolin-1 inhibits matrix metalloproteinase-2 activity in the heart. J Mol Cell Cardiol 42:896-901. doi:10.1016/j.yjmcc.2007.01.008 (Pubitemid 46527597)
29. Coker ML, Doscher MA, Thomas CV, Galis ZS, Spinale FG (1999) Matrix metalloproteinase synthesis and expression in isolated LV myocyte preparations. Am J Physiol Heart Circ Physiol 277:H777-H787 (Pubitemid 29415994)
30. Coussens LM, Fingleton B, Matrisian LM (2002) Matrix metalloproteinase inhibitors and cancer - trials and tribulations. Science 295:2387-2392. doi:10.1126/science.1067100 (Pubitemid 34270240)
31. Descamps FJ, Martens E, Opdenakker G (2002) Analysis of gelatinases in complex biological fluids and tissue extracts. Lab Invest 82:1607-1608. doi:10.1097/01.LAB.0000038556.54069.73 (Pubitemid 35332920)
32. Donato M, D'Annunzio V, Buchholz B, Miksztowicz V, Carrion CL, Valdez LB, Zaobornyj T, Schreier L, Wikinski R, Boveris A, Berg G, Gelpi RJ (2010) Role of matrix metalloproteinase-2 in the cardioprotective effect of ischaemic postconditioning. Exp Physiol 95:274-281. doi:10.1113/expphysiol.2009.049874
33. Donnini S, Monti M, Roncone R, Morbidelli L, Rocchigiani M, Oliviero S, Casella L, Giachetti A, Schulz R, Ziche M (2008) Peroxynitrite inactivates human-tissue inhibitor of metalloproteinase-4. FEBS Lett 582:1135-1140. doi:10.1016/j.febslet.2008.02.080
34. Dorman G, Kocsis-Szommer K, Spadoni C, Ferdinandy P (2007) MMP inhibitors in cardiac diseases: an update. Recent Pat Cardiovasc Drug Discov 2:186-194. doi:10.2174/157489007782418964 (Pubitemid 350213804)
35. Ducharme A, Frantz S, Aikawa M, Rabkin E, Lindsey M, Rohde LE, Schoen FJ, Kelly RA, Werb Z, Libby P, Lee RT (2000) Targeted deletion of matrix metalloproteinase-9 attenuates left ventricular enlargement and collagen accumulation after experimental myocardial infarction. J Clin Invest 106:55-62. doi:10.1172/jci8768 (Pubitemid 30437240)
36. Fan X, Schulz R (2012) Matrix metalloproteinase-2: an emerging biomarker for reperfusion injury following percutaneous coronary intervention. Heart 98:1-2. doi:10.1136/heartjnl-2011-300886
37. Fert-Bober J, Leon H, Sawicka J, Basran RS, Devon RM, Schulz R, Sawicki G (2008) Inhibiting matrix metalloproteinase-2 reduces protein release into coronary effluent from isolated rat hearts during ischemia-reperfusion. Basic Res Cardiol 103:431-443. doi:10.1007/s00395-008-0727-y
38. Finegan BA (2009) What about the other two-thirds of the cardiac cycle? Can J Anaesth 56:348-351. doi:10.1007/s12630-009-9072-3
39. Fingleton B (2007) Matrix metalloproteinases as valid clinical targets. Curr Pharm Des 13:333-346. doi:10.2174/138161207779313551
40. Frears ER, Zhang Z, Blake DR, O'Connell JP, Winyard PG (1996) Inactivation of tissue inhibitor of metalloproteinase-1 by peroxynitrite. FEBS Lett 381:21-24. doi:10.1016/0014-5793(96)00065-8 (Pubitemid 26070416)
41. Galis ZS, Sukhova GK, Lark MW, Libby P (1994) Increased expression of matrix metalloproteinases and matrix degrading activity in vulnerable regions of human atherosclerotic plaques. J Clin Invest 94:2493-2503. doi:10.1172/ jci117619 (Pubitemid 24379627)
42. Gao L, Chen L, Lu Z, Gao H, Wu L, Chen Y, Zhang C, Jiang Y, Jing Q, Zhang YY, Yang HT (2014) Activation of α1B-adrenoceptors contributes to intermittent hypobaric hypoxia-improved post-ischemic myocardial performance via inhibiting MMP-2 activation. Am J Physiol Heart Circ Physiol 306:H1569-H1581. doi:10.1152/ajpheart.00772.2013
43. Garcia RA, Go KV, Villarreal FJ (2007) Effects of timed administration of doxycycline or methylprednisolone on postmyocardial infarction inflammation and left ventricular remodeling in the rat heart. Mol Cell Biochem 300:159-169. doi:10. 1007/s11010-006-9379-0
44. García RA, Pantazatos DP, Gessner CR, Go KV, Woods VL, Villarreal FJ (2005) Molecular interactions between matrilysin and the matrix metalloproteinase inhibitor doxycycline investigated by deuterium exchange mass spectrometry. Mol Pharmacol 67:1128-1136. doi:10.1124/mol.104.006346
45. Giricz Z, Lalu MM, Csonka C, Bencsik P, Schulz R, Ferdinandy P (2006) Hyperlipidemia attenuates the infarct size-limiting effect of ischemic preconditioning: role of matrix metalloproteinase-2 inhibition. J Pharmacol Exp Ther 316:154-161. doi:10.1124/jpet.105.091140 (Pubitemid 41832592)
46. Glenn L (1999) Antibiotic use and risk of myocardial infarction. JAMA 282(21):1997
47. Goldberg GI, Wilhelm SM, Kronberger A, Bauer EA, Grant GA, Eisen AZ (1986) Human fibroblast collagenase. Complete primary structure and homology to an oncogene transformationinduced rat protein. J Biol Chem 261:6600-6605 (Pubitemid 17204179)
48. Golub LM, Lee H-M, Ryan ME, Giannobile WV, Payne J, Sorsa T (1998) Tetracyclines inhibit connective tissue breakdown by multiple non-antimicrobial mechanisms. Adv Dent Res 12:12-26. doi:10.1177/08959374980120010501
49. Griffin MO, Jinno M, Miles LA, Villarreal FJ (2005) Reduction of myocardial infarct size by doxycycline: a role for plasmin inhibition. Mol Cell Biochem 270:1-11. doi:10.1007/s11010-005-2540-3 (Pubitemid 40425232)
50. Gross J, Lapiere CM (1962) Collagenolytic activity in amphibian tissues: a tissue culture assay. Proc Natl Acad Sci USA 48:1014-1022
51. Gu Z, Kaul M, Yan B, Kridel SJ, Cui J, Strongin A, Smith JW, Liddington RC, Lipton SA (2002) S-nitrosylation of matrix metalloproteinases: signaling pathway to neuronal cell death. Science 297:1186-1190. doi:10.1126/science. 1073634 (Pubitemid 36193354)
52. Hayashidani S, Tsutsui H, Ikeuchi M, Shiomi T, Matsusaka H, Kubota T, Imanaka-Yoshida K, Itoh T, Takeshita A (2003) Targeted deletion of MMP-2 attenuates early LV rupture and late remodeling after experimental myocardial infarction. Am J Physiol Heart Circ Physiol 285:H1229-H1235. doi:10.1152/ajpheart.00207.2003 (Pubitemid 37048181)
53. Heusch G (2013) Cardioprotection: chances and challenges of its translation to the clinic. Lancet 381:166-175. doi:10.1016/S0140-6736(12)60916-7
54. Heusch G, Libby P, Gersh B, Yellon D, Böhm M, Lopaschuk G, Opie L (2014) Cardiovascular remodelling in coronary artery disease and heart failure. Lancet 383:1933-1943. doi:10.1016/S0140-6736(14)60107-0
55. Heymans S, Luttun A, Nuyens D, Theilmeier G, Creemers E, Moons L, Dyspersin GD, Cleutjens JPM, Shipley M, Angellilo A, Levi M, Nue O, Baker A, Keshet E, Lupu F, Herbert JM, Smits JFM, Shapiro SD, Baes M, Borgers M, Collen D, Daemen MJAP, Carmeliet P (1999) Inhibition of plasminogen activators or matrix metalloproteinases prevents cardiac rupture but impairs therapeutic angiogenesis and causes cardiac failure. Nat Med 5:1135-1142. doi:10.1038/13459 (Pubitemid 29474417)
56. Hudson MP, Armstrong PW, Ruzyllo W, Brum J, Cusmano L, Krzeski P, Lyon R, Quinones M, Theroux P, Sydlowski D, Kim HE, Garcia MJ, Jaber WA, Weaver WD (2006) Effects of selective matrix metalloproteinase inhibitor (PG-116800) to prevent ventricular remodeling after myocardial infarction: results of the PREMIER (Prevention of Myocardial Infarction Early Remodeling) trial. J Am Coll Cardiol 48:15-20. doi:10.1016/j.jacc.2006.02.055 (Pubitemid 43929218)
57. Hughes BG, Fan X, Cho WJ, Schulz R (2014) MMP-2 is localized to the mitochondria-associated membrane of the heart. Am J Physiol Heart Circ Physiol 306:H764-H770. doi:10.1152/ajpheart.00909.2013
58. Ikonomidis JS, Hendrick JW, Parkhurst AM, Herron AR, Escobar PG, Dowdy KB, Stroud RE, Hapke E, Zile MR, Spinale FG (2005) Accelerated LV remodeling after myocardial infarction in TIMP-1-deficient mice: effects of exogenous MMP inhibition. Am J Physiol Heart Circ Physiol 288:H149-H158. doi:10.1152/ajpheart. 00370.2004 (Pubitemid 40023842)
59. Itoh T, Ikeda T, Gomi H, Nakao S, Suzuki T, Itohara S (1997) Unaltered secretion of b-amyloid precursor protein in gelatinase A (matrix metalloproteinase 2)-deficient mice. J Biol Chem 272:22389-22392. doi:10.1074/jbc.272.36.22389 (Pubitemid 27386043)
60. Jacob-Ferreira AL, Kondo MY, Baral PK, James MNG, Holt A, Fan X, Schulz R (2013) Phosphorylation status of 72 kDaMMP-2 determines its structure and activity in response to peroxynitrite. PLoS One 8:e71794. doi:10.1371/journal. pone.0071794
61. Jayasankar V, Woo YJ, Bish LT, Pirolli TJ, Berry MF, Burdick J, Bhalla RC, Sharma RV, Gardner TJ, Sweeney HL (2004) Inhibition of matrix metalloproteinase activity by TIMP-1 gene transfer effectively treats ischemic cardiomyopathy. Circulation 110:II-180-II-186. doi:10.1161/01.cir.0000138946. 29375.49
62. Kaludercic N, Lindsey ML, Tavazzi B, Lazzarino G, Paolocci N (2008) Inhibiting metalloproteases with PD 166793 in heart failure: impact on cardiac remodeling and beyond. Cardiovasc Drug Rev 26:24-37. doi:10.1111/j.1527-3466. 2007.00034.x (Pubitemid 351421776)
63. Kandasamy AD, Chow AK, Ali MAM, Schulz R (2010) Matrix metalloproteinase-2 and myocardial oxidative stress injury: beyond the matrix. Cardiovasc Res 85:413-423. doi:10.1093/cvr/cvp268
64. Keeley EC, Boura JA, Grines CL (2003) Primary angioplasty versus intravenous thrombolytic therapy for acute myocardial infarction: a quantitative review of 23 randomised trials. Lancet 361:13-20. doi:10.1016/S0140-6736(03) 12113-7 (Pubitemid 36050955)
65. Koenig GC, Rowe RG, Day SM, Sabeh F, Atkinson JJ, Cooke KR, Weiss SJ (2012) MT1-MMP-dependent remodeling of cardiac extracellular matrix structure and function following myocardial infarction. Am J Pathol 180:1863-1878. doi:10.1016/j.ajpath.2012.01.022
66. Koskivirta I, Kassiri Z, Rahkonen O, Kiviranta R, Oudit GY, McKee TD, Kyto V, Saraste A, Jokinen E, Liu PP, Vuorio E, Khokha R (2010) Mice with tissue inhibitor of metalloproteinases 4 (TIMP4) deletion succumb to induced myocardial infarction but not to cardiac pressure overload. J Biol Chem 285:24487-24493. doi:10.1074/jbc.M110.136820
67. Krishnamurthy P, Peterson JT, Subramanian V, Singh M, Singh K (2009) Inhibition of matrix metalloproteinases improves left ventricular function in mice lacking osteopontin after myocardial infarction. Mol Cell Biochem 322:53-62. doi:10.1007/s11010-008-9939-6
68. Kryzhanovskii SA, Ionova EO, Stolyaruk VN, Tsorin IB, Vititnova MB (2013) Effect of metalloproteinase inhibitor on early postinfarction remodeling in the most acute phase of myocardial infarction. Bull Exp Biol Med 156:19-24. doi:10.1007/s10517-013-2267-1
69. Kwan JA, Schulze CJ, Wang W, Leon H, Sariahmetoglu M, Sung M, Sawicka J, Sims DE, Sawicki G, Schulz R (2004) Matrix metalloproteinase-2 (MMP-2) is present in the nucleus of cardiac myocytes and is capable of cleaving poly (ADP-ribose) polymerase (PARP) in vitro. FASEB J 18:690-692. doi:10.1096/fj.02-1202fje
70. Labossiere JR, Pelletier JS, Ali MA, Thiesen A, Schulz R, Bigam DL, Cheung PY (2013) Postresuscitation administration of doxycycline preserves cardiac contractile function in hypoxia-reoxygenation injury of newborn piglets. Crit Care Med 42:e260-e269. doi:10.1097/CCM.0000000000000135
71. Lalu MM, Pasini E, Schulze CJ, Ferrari-Vivaldi M, Ferrari-Vivaldi G, Bachetti T, Schulz R (2005) Ischaemia-reperfusion injury activates matrix metalloproteinases in the human heart. Eur Heart J 26:27-35. doi:10.1093/eurheartj/ehi007 (Pubitemid 40221120)
72. Lalu MM, Csonka C, Giricz Z, Csont T, Schulz R, Ferdinandy P (2002) Preconditioning decreases ischemia/reperfusion-induced release and activation of matrix metalloproteinase-2. Biochem Biophys Res Commun 296:937-941. doi:10.1016/S0006-291X(02)02019-3
73. Lindsey ML, Escobar GP, Mukherjee R, Goshorn DK, Sheats NJ, Bruce JA, Mains IM, Hendrick JK, Hewett KW, Gourdie RG, Matrisian LM, Spinale FG (2006) Matrix metalloproteinase-7 affects connexin-43 levels, electrical conduction, and survival after myocardial infarction. Circulation 113:2919-2928. doi:10.1161/circulationaha.106.612960 (Pubitemid 44297233)
74. Lindsey ML, Escobar GP, Dobrucki LW, Goshorn DK, Bouges S, Mingoia JT, McClister DM, Su H, Gannon J, MacGillivray C, Lee RT, Sinusas AJ, Spinale FG (2005) Matrix metalloproteinase-9 gene deletion facilitates angiogenesis after myocardial infarction. Am J Physiol Heart Circ Physiol 290:H232-H239. doi:10.1152/ajpheart.00457.2005
75. Lindsey ML, Gannon J, Aikawa M, Schoen FJ, Rabkin E, Lopresti-Morrow L, Crawford J, Black S, Libby P, Mitchell PG, Lee RT (2002) Selective matrix metalloproteinase inhibition reduces left ventricular remodeling but does not inhibit angiogenesis after myocardial infarction. Circulation 105:753-758. doi:10.1161/hc0602.103674 (Pubitemid 34157381)
76. Lindsey ML, Zamilpa R (2012) Temporal and spatial expression of matrix metalloproteinases and tissue inhibitors of metalloproteinases following myocardial infarction. Cardiovasc Ther 30:31-41. doi:10.1111/j.1755-5922.2010. 00207.x
77. Lovett DH, Mahimkar R, Raffai RL, Cape L, Maklashina E, Cecchini G, Karliner JS (2012) A novel intracellular isoform of matrix metalloproteinase-2 induced by oxidative stress activates innate immunity. PLoS One 7:e34177. doi:10.1371/journal.pone.0034177
78. Lovett DH, Mahimkar R, Raffai RL, Cape L, Zhu B-Q, Jin Z-Q, Baker AJ, Karliner JS (2013) N-terminal truncated intracellular matrix metalloproteinase-2 induces cardiomyocyte hypertrophy, inflammation and systolic heart failure. PLoS One 8:e68154. doi:10.1371/journal.pone.0068154
79. Matsumura S, Iwanaga S, Mochizuki S, Okamoto H, Ogawa S, Okada Y (2005) Targeted deletion or pharmacological inhibition of MMP-2 prevents cardiac rupture after myocardial infarction in mice. J Clin Invest 115:599-609. doi:10.1172/jci22304 (Pubitemid 40322234)
80. Matsunaga T, Abe N, Kameda K, Hagii J, Fujita N, Onodera H, Kamata T, Ishizaka H, Hanada H, Osanai T, Okumura K (2005) Circulating level of gelatinase activity predicts ventricular remodeling in patients with acute myocardial infarction. Int J Cardiol 105:203-208. doi:10.1016/j.ijcard.2005.01.011 (Pubitemid 41512488)
81. Meier CR, Derby LE, Jick SS, Vasilakis C, Jick H (1999) Antibiotics and risk of subsequent first-time acute myocardial infarction. JAMA 281:427-431. doi:10.1001/jama.281.5.427 (Pubitemid 29069440)
82. Mukherjee R, Brinsa TA, Dowdy KB, Scott AA, Baskin JM, Deschamps AM, Lowry AS, Escobar GP, Lucas DG, Yarbrough WM, Zile MR, Spinale FG (2003) Myocardial infarct expansion and matrix metalloproteinase inhibition. Circulation 107:618-625. doi:10.1161/01.CIR.0000046449.36178.00 (Pubitemid 36176814)
83. Müller AL, Freed D, Dhalla NS (2013) Activation of proteases and changes in Na+-K+-ATPase subunits in hearts subjected to ischemia-reperfusion. J Appl Physiol 114:351-360. doi:10.1152/japplphysiol.01239.2012
84. Murphy G, Nagase H (2008) Progress in matrix metalloproteinase research. Mol Aspects Med 29:290-308. doi:10.1016/j.mam.2008.05.002
85. Murphy G (2011) Tissue inhibitors of metalloproteinases. Genome Biol 12:233. doi:10.1186/gb-2011-12-11-233
86. Nelson KK, Melendez JA (2004) Mitochondrial redox control of matrix metalloproteinases. Free Radic Biol Med 37:768-784. doi:10.1016/j.freeradbiomed. 2004.06.008 (Pubitemid 39078549)
87. Nilsson L, Hallen J, Atar D, Jonasson L, Swahn E (2012) Early measurements of plasma matrix metalloproteinase-2 predict infarct size and ventricular dysfunction in ST-elevation myocardial infarction. Heart 98:31-36. doi:10.1136/heartjnl-2011-300079
88. Okamoto T, Akaike T, Sawa T, Miyamoto Y, van der Vliet A, Maeda H (2001) Activation of matrix metalloproteinases by peroxynitrite-induced protein S-glutathiolation via disulfide S-oxide formation. J Biol Chem 276:29596-29602. doi:10.1074/jbc.M102417200
89. Ostadal B, Netuka I, Maly J, Besik J, Ostadalova I (2009) Gender differences in cardiac ischemic injury and protection - experimental aspects. Exp Biol Med 234:1011-1019. doi:10.3181/0812-mr-362
90. Peterson JT, Li H, Dillon L, Bryant JW (2000) Evolution of matrix metalloprotease and tissue inhibitor expression during heart failure progression in the infarcted rat. Cardiovasc Res 46:307-315. doi:10.1016/s0008-6363(00) 00029-8 (Pubitemid 30204603)
91. Peterson JT (2004) Matrix metalloproteinase inhibitor development and the remodeling of drug discovery. Heart Fail Rev 9:63-79. doi:10.1023/B:HREV. 0000011395.11179.af
92. Rohde LE, Ducharme A, Arroyo LH, Aikawa M, Sukhova GH, Lopez-Anaya A, McClure KF, Mitchell PG, Libby P, Lee RT (1999) Matrix metalloproteinase inhibition attenuates early left ventricular enlargement after experimental myocardial infarction in mice. Circulation 99:3063-3070. doi:10.1161/01.cir.99. 23.3063 (Pubitemid 29270438)
93. Romero-Perez D, Agrawal A, Jacobsen J, Yan Y, Thomas R, Cohen S, Villarreal F (2009) Effects of novel semiselective matrix metalloproteinase inhibitors on ex vivo cardiac structure-function. J Cardiovasc Pharmacol 53:452-461. doi:10.1097/FJC. 0b013e3181a6aa83
94. Romero-Perez D, Fricovsky E, Yamasaki KG, Griffin M, Barraza-Hidalgo M, Dillmann W, Villarreal F (2008) Cardiac uptake of minocycline and mechanisms for in vivo cardioprotection. J Am Coll Cardiol 52:1086-1094. doi:10.1016/j.jacc. 2008.06.028
95. Sariahmetoglu M, Skrzypiec-Spring M, Youssef N, Jacob-Ferreira ALB, Sawicka J, Holmes C, Sawicki G, Schulz R (2012) Phosphorylation status of matrix metalloproteinase 2 in myocardial ischaemia-reperfusion injury. Heart 98:656-662. doi:10.1136/heartjnl-2011-301250
96. Sariahmetoglu M, Crawford BD, Leon H, Sawicka J, Li L, Ballermann BJ, Holmes C, Berthiaume LG, Holt A, Sawicki G, Schulz R (2007) Regulation of matrix metalloproteinase-2 (MMP-2) activity by phosphorylation. FASEB J 21:2486-2495. doi:10.1096/fj.06-7938com (Pubitemid 47230678)
97. Sato H, Takino T, Okada Y, Cao J, Shinagawa A, Yamamoto E, Seiki M (1994) A matrix metalloproteinase expressed on the surface of invasive tumor-cells. Nature 370:61-65. doi:10.1038/370061a0 (Pubitemid 24216953)
98. Sawicki G, Leon H, Sawicka J, Sariahmetoglu M, Schulze CJ, Scott PG, Szczesna-Cordary D, Schulz R (2005) Degradation of myosin light chain in isolated rat hearts subjected to ischemia-reperfusion injury. Circulation 112:544-552. doi:10.1161/circulationaha.104.531616
99. Schulze CJ, Wang W, Suarez-Pinzon WL, Sawicka J, Sawicki G, Schulz R (2003) Imbalance between tissue inhibitor of metalloproteinase-4 and matrix metalloproteinases during acute myoctardial ischemia-reperfusion injury. Circulation 107:2487-2492. doi:10.1161/01.cir.0000065603.09430.58 (Pubitemid 36605233)
100. Schulze CJ, Castro MM, Kandasamy AD, Cena J, Bryden C, Wang SH, Koshal A, Tsuyuki RT, Finegan BA, Schulz R (2013) Doxycycline reduces cardiac matrix metalloproteinase-2 activity but does not ameliorate myocardial dysfunction during reper-fusion in coronary artery bypass patients undergoing cardiopulmonary bypass. Crit Care Med 41:2512-2520. doi:10.1097/CCM. 0b013e318292373c
101. Singh RB, Hryshko L, Freed D, Dhalla NS (2012) Activation of proteolytic enzymes and depression of the sarcolemmal Na+-K+-ATPase in ischemia-reperfused heart may be mediated through oxidative stress. Can J Physiol Pharmacol 90:249-260. doi:10.1139/y11-128
102. Smith GN Jr, Mickler EA, Hasty KA, Brandt KD (1999) Specificity of inhibition of matrix metalloproteinase activity by doxycycline: relationship to structure of the enzyme. Arthritis Rheum 42:1140-1146. doi:10.1002/1529- 0131(199906)42: 6〈1140:AID-ANR10〉3.0.CO;2-7
103. Smith GN Jr, Brandt KD, Hasty KA (1996) Activation of recombinant human neutrophil procollagenase in the presence of doxycycline results in fragmentation of the enzyme and loss of enzyme activity. Arthritis Rheum 39:235-244. doi:10.1002/art.1780390209 (Pubitemid 26065263)
104. Spinale F, Wilbur N (2009) Matrix metalloproteinase therapy in heart failure. Curr Treat Options Cardiovasc Med 11:339-346. doi:10.1007/s11936-009- 0034-4
105. Spinale FG (2002) Matrix metalloproteinases: regulation and dysregulation in the failing heart. Circ Res 90:520-530. doi:10.1161/01.res.0000013290.12884. a3
106. Spinale FG, Koval CN, Deschamps AM, Stroud RE, Ikonomidis JS (2008) Dynamic changes in matrix metalloproteinase activity within the human myocardial interstitium during myocardial arrest and reperfusion. Circulation 118:S16-S23. doi:10.1161/circulationaha.108.786640
107. Spinale FG (2007) Myocardial matrix remodeling and the matrix metalloproteinases: influence on cardiac form and function. Physiol Rev 87:1285-1342. doi:10.1152/physrev.00012.2007
108. Squire IB, Evans J, Ng LL, Loftus IM, Thompson MM (2004) Plasma MMP-9 and MMP-2 following acute myocardial infarction in man: correlation with echocardiographic and neurohumoral parameters of left ventricular dysfunction. J Card Fail 10:328-333. doi:10.1016/j.cardfail.2003.11.003 (Pubitemid 39092685)
109. Sung MM, Schulz CG, Wang W, Sawicki G, Bautista-López NL, Schulz R (2007) Matrix metalloproteinase-2 degrades the cytoskeletal protein [alpha]-actinin in peroxynitrite mediated myocardial injury. J Mol Cell Cardiol 43:429-436. doi:10.1016/j.yjmcc.2007.07.055 (Pubitemid 47451426)
110. Takai S, Jin D, Inagaki S, Yamamoto D, Tanaka K, Miyazaki M (2007) Significance of matrix metalloproteinase-9 in cardiac dysfunction during the very acute phase after myocardial infarction in hamsters. Eur J Pharmacol 572:57-60. doi:10.1016/j.ejphar.2007.07.001 (Pubitemid 47374682)
111. Tessone A, Feinberg MS, Barbash IM, Reich R, Holbova R, Richmann M, Mardor Y, Leor J (2005) Effect of matrix metalloproteinase inhibition by doxycycline on myocardial healing and remodeling after myocardial infarction. Cardiovasc Drugs Ther 19:383-390. doi:10.1007/s10557-005-5201-6 (Pubitemid 43228149)
112. Van Eyk JE, Powers F, Law W, Larue C, Hodges RS, Solaro RJ (1998) Breakdown and release of myofilament proteins during ischemia and ischemia/reperfusion in rat hearts: identification of degradation products and effects on the pCa-force relation. Circ Res 82:261-271. doi:10.1161/01.res.82.2. 261 (Pubitemid 28080109)
113. van Holten TC, Waanders LF, de Groot PG, Vissers J, Hoefer IE, Pasterkamp G, Prins MW, Roest M (2013) Circulating biomarkers for predicting cardiovascular disease risk; a systematic review and comprehensive overview of meta-analyses. PLoS One 8:e62080. doi:10.1371/journal.pone.0062080
114. Van Wart HE, Birkedal-Hansen H (1990) The cysteine switch: a principle of regulation of metalloproteinase activity with potential applicability to the entire matrix metalloproteinase gene family. Proc Natl Acad Sci USA 87:5578-5582. doi:10.1073/pnas.87.14.5578
115. Vanhoutte D, Schellings M, Pinto Y, Heymans S (2006) Relevance of matrix metalloproteinases and their inhibitors after myocardial infarction: a temporal and spatial window. Cardiovasc Res 69:604-613. doi:10.1016/j.cardiores.2005.10. 002 (Pubitemid 43139724)
116. Viappiani S, Nicolescu AC, Holt A, Sawicki G, Crawford BD, León H, van Mulligen T, Schulz R (2009) Activation and modulation of 72 kDa matrix metalloproteinase-2 by peroxynitrite and glutathione. Biochem Pharmacol 77:826-834. doi:10.1016/j.bcp.2008.11.004
117. Villarreal FJ, Griffin M, Omens J, Dillmann W, Nguyen J, Covell J (2003) Early short-term treatment with doxycycline modulates postinfarction left ventricular remodeling. Circulation 108:1487-1492. doi:10.1161/01.cir. 0000089090.05757.34 (Pubitemid 37176456)
118. Wang W, Schulze CJ, Suarez-Pinzon WL, Dyck JRB, Sawicki G, Schulz R (2002) Intracellular action of matrix metalloproteinase-2 accounts for acute myocardial ischemia and reperfusion injury. Circulation 106:1543-1549. doi:10.1161/01.cir.0000028818.33488.7b
119. Will H, Atkinson SJ, Butler GS, Smith B, Murphy G (1996) The soluble catalytic domain of membrane type 1 matrix metalloproteinase cleaves the propeptide of progelatinase A and initiates autoproteolytic activation: regulation by TIMP-2 and TIMP-3. J Biol Chem 271:17119-17123. doi:10.1074/jbc.271.29.17119 (Pubitemid 26244261)
120. Woolley DE, Glanville RW, Crossley MJ, Evanson JM (1975) Purification of rheumatoid synovial collagenase and its action on soluble and insoluble collagen. Eur J Biochem 54:611-622. doi:10.1111/j.1432-1033.1975.tb04173.x
121. Yamada A, Uegaki A, Nakamura T, Ogawa K (2000) ONO-4817, an orally active matrix metalloproteinase inhibitor, prevents lipopolysaccharide-induced proteoglycan release from the joint cartilage in guinea pigs. Inflamm Res 49:144-146. doi:10.1007/s000110050573 (Pubitemid 30262710)
122. Yan P, Chen KJ, Wu J, Sun L, Sung HW, Weisel RD, Xie J, Li RK (2014) The use of MMP2 antibody-conjugated cationic microbubble to target the ischemic myocardium, enhance Timp3 gene transfection and improve cardiac function.
123. Yarbrough WM, Mukherjee R, Escobar GP, Mingoia JT, Sample JA, Hendrick JW, Dowdy KB, McLean JE, Lowry AS, O'Neill TP, Spinale FG (2003) Selective targeting and timing of matrix metalloproteinase inhibition in post-myocardial infarction remodeling. Circulation 108:1753-1759. doi:10.1161/01.cir.0000091087. 78630.79 (Pubitemid 37243666)
124. Yasmin W, Strynadka KD, Schulz R (1997) Generation of peroxynitrite contributes to ischemia-reperfusion injury in isolated rat hearts. Cardiovasc Res 33:422-432. doi:10.1016/s0008-6363(96)00254-4 (Pubitemid 27072648)
125. Yellon DM, Hausenloy DJ (2007) Myocardial reperfusion injury. N Engl J Med 357:1121-1135. doi:10.1056/NEJMra071667
126. Zavadzkas JA, Mukherjee R, Rivers WT, Patel RK, Meyer EC, Black LE, McKinney RA, Oelsen JM, Stroud RE, Spinale FG (2011) Direct regulation of membrane type 1 matrix metalloproteinase following myocardial infarction causes changes in survival, cardiac function, and remodeling. Am J Physiol Heart Circ Physiol 301:H1656-H1666. doi:10.1152/ajpheart.00141.2011
127. Zavadzkas JA, Stroud RE, Bouges S, Mukherjee R, Jones JR, Patel RK, McDermott PJ, Spinale FG (2014) Targeted overexpression of tissue inhibitor of matrix metalloproteinase-4 modifies post-myocardial infarction remodeling in mice. Circ Res 114:1435-1445. doi:10.1161/circresaha.114.303634
128. Zhou H-Z, Ma X, Gray MO, Zhu B, Nguyen AP, Baker AJ, Simonis U, Cecchini G, Lovett DH, Karliner JS (2007) Transgenic MMP-2 expression induces latent cardiac mitochondrial dysfunction. Biochem Biophys Res Commun 358:189-195. doi:10.1016/j.bbrc.2007.04.094 (Pubitemid 46719101)